Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone‐releasing hormone‐agonist therapy for prostate cancer

Taxel, Pamela; Dowsett, Robert J.; Richter, Lee A.; Fall, Pamela; Klepinger, Alison; Albertsen, Peter C.

doi:10.1111/j.1464-410x.2010.09329.x

Cited by 46 publications

(50 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The bone resorption markers N-telopeptide and C-telopeptide increased significantly (21% and 55%, respectively) in this group [54].…”

Section: Clinical Trial Evidencementioning

confidence: 69%

“…In a 6-month randomized double-blinded, placebo-controlled trial in 40 men undergoing luteinizing hormonereleasing hormone agonist therapy, Taxel et al [54] evaluated risedronate plus 600 mg calcium and 400 IU vitamin D versus an "identical placebo" plus 600 mg calcium with 400 IU vitamin D. Significant decreases in BMD in the femoral neck (Ϫ2%) and total hip (Ϫ2.2%) and a nonsignificant decrease in BMD in the lumbar spine were observed in the placebo plus calcium and vitamin D (Ca-D) group. The bone resorption markers N-telopeptide and C-telopeptide increased significantly (21% and 55%, respectively) in this group [54].…”

Section: Clinical Trial Evidencementioning

confidence: 99%

See 1 more Smart Citation

Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review

Datta

Schwartz

2012

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Describe the prevalence of bone loss with androgen deprivation therapy for prostate cancer.2. Discuss the possible increased risk of cardiovascular disease and of advanced prostate cancer with high calcium intake.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTBackground. Loss of bone mineral density is an unintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. Methods. We reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy.Results. Whether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical

show abstract

“…The bone resorption markers N-telopeptide and C-telopeptide increased significantly (21% and 55%, respectively) in this group [54].…”

Section: Clinical Trial Evidencementioning

confidence: 69%

Section: Clinical Trial Evidencementioning

confidence: 99%

Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review

Datta

Schwartz

2012

The Oncologist

View full text Add to dashboard Cite

show abstract

“…We included 12 potentially eligible trials and subsequently obtained data for ten of these ( Figure 1). Two trials (Magno et al, 2005;Taxel et al, 2010) including a total of 194 patients were not available because the investigators felt unable to provide the data for inclusion in this metaanalysis. Of the 1017 participants, 512 were randomised to receive bisphosphonates and 505 to placebo or other medical treatment.…”

Section: Resultsmentioning

confidence: 99%

Bisphosphonates for Osteoporosis in Nonmetastatic Prostate Cancer Patients Receiving Androgen-deprivation Therapy: A Systematic Review and Meta-analysis

Li¹,

Du²,

Teng³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

This systematic review was conducted to assess the efficacy and safety of bisphosphonates for prevention and treatment of osteopenia or osteoporosis in men with non-metastatic prostate cancer receiving androgendeprivation therapy. We searched for randomised controlled trials (RCTs) of bisphosphonates compared with placebo from Pubmed, Embase, the Cochrane Library, and ISI -Science Citation Index. Meta-analyses of prespecified outcomes (bone mineral density, fractures, and adverse events) were performed using Review Manager. Ten RCTs with a total patient population of 1,017 were identified. There was generally more improvement in bone mineral density of the lumbar spine for patients who received bisphosphonate treatment than placebo or other medical treatment at 12 months (WMD 6.02,95%CI 5.39 to 6.65). Similar effects were also observed for total hip, trochanter or femoral neck bone mineral density. However, there was no significant reduction in fractures. Fever and gastrointestinal symptoms were the most common adverse events (10.4% vs. 1.2%; 0.10% vs. 0.03%). Currently, our meta-analysis suggested that oral and intravenous bisphosphonates caused a rapid increase in spine and hip or femoral BMD in non-metastatic prostate cancer patients receiving androgen-deprivation therapy. Fever and gastrointestinal symptoms were common with the use of bisphosphonates. These short-term trials (maximum of 12 months) did not show fracture reduction. In future, more efficient performance of higher quality, more rigorous, large sample, long-term randomised controlled trials (>12 months) are needed where outcomes are detailed.

show abstract

“…The control group was set but not randomized. 7 Taxel et al 18 recently reported the results of a randomized, double-blind, placebo-controlled trial. In their study, 40 men receiving luteinizing hormone-releasing hormone agonist for 6 months for locally advanced PCa were randomized in the risedronate administration group and the control group.…”

Section: Discussionmentioning

confidence: 99%

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Izumi

Mizokami

Sugimoto

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss. Although we reported previously that risedronate significantly recovers bone mineral density (BMD) for up to 12 months, there have been no reports with longer follow-up periods to date. This study extended our earlier series extending the follow-up period to 24 months. Eligible patients had histologically confirmed PCa without lumbar spine metastasis and underwent ADT. Lumbar spine BMD, urinary deoxypyridinoline (uDPD) and serum bone alkaline phosphatase were measured at 6, 12 and 24 months. Among the total of 96 patients, we analyzed 26 and 18 patients in risedronate administration and control groups, respectively. BMD relative to the young adult mean ratio, uDPD and serum bone alkaline phosphatase of the risedronate administration group recovered significantly after 24 months compared with the control group (Po0.0001, P ¼ 0.0001, and Po0.0001, respectively). Transient blurred vision, malaise and vertigo were observed in 1 patient each among the 46 patients treated with risedronate within 28 days after first administration. Oral administration of risedronate is safe and effective for the recovery of ADT-induced bone loss in PCa patients even at 24 months after commencement of treatment.

show abstract

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone‐releasing hormone‐agonist therapy for prostate cancer

Cited by 46 publications

References 18 publications

Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review

Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review

Bisphosphonates for Osteoporosis in Nonmetastatic Prostate Cancer Patients Receiving Androgen-deprivation Therapy: A Systematic Review and Meta-analysis

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Contact Info

Product

Resources

About